118 related articles for article (PubMed ID: 223123)
1. [The treatment of advanced malignant melanoma with vaccina oncolysates (author's transl)].
Wallack MK
Nouv Presse Med; 1979 May; 8(23):1919-21. PubMed ID: 223123
[TBL] [Abstract][Full Text] [Related]
2. [Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus].
Doré JF; Portoukalian J; Berthier-Vergnes O; Jacubovich R; Genève J; Bailly M; Lefthériotis E; Weissbrod A; Mayer M
Bull Cancer; 1990; 77(9):881-91. PubMed ID: 2224160
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO).
Wallack MK; McNally K; Michaelides M; Bash J; Bartolucci A; Siegler H; Balch C; Wanebo H
Am Surg; 1986 Mar; 52(3):148-51. PubMed ID: 3513682
[TBL] [Abstract][Full Text] [Related]
4. A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment.
Wallack MK; Meyer M; Bourgoin A; Doré JF; Leftheriotis E; Carcagne J; Koprowski H
J Biol Response Mod; 1983; 2(6):586-96. PubMed ID: 6663322
[TBL] [Abstract][Full Text] [Related]
5. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates.
Berthier-Vergnes O; Portoukalian J; Lefthériotis E; Doré JF
Cancer Res; 1994 May; 54(9):2433-9. PubMed ID: 8162593
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
[TBL] [Abstract][Full Text] [Related]
7. [Local immunotherapy. Alternative therapy for malignant cutaneous lesions (demonstration on 30 patients with malignant melanoma) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1979 Mar; 91(5):150-4. PubMed ID: 425533
[TBL] [Abstract][Full Text] [Related]
8. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
[TBL] [Abstract][Full Text] [Related]
9. Immunological studies on malignant melanomas of man.
Romsdahl MM; Cox IS
Yale J Biol Med; 1973 Dec; 46(5):693-701. PubMed ID: 4205125
[No Abstract] [Full Text] [Related]
10. [The characterization of tumour-associated membrane-bound antigens and their implementation in the treatment of malignant melanoma (author's transl)].
Kokoschka EM
Wien Klin Wochenschr Suppl; 1979; 97():3-32. PubMed ID: 106559
[No Abstract] [Full Text] [Related]
11. [Vaccine therapy of malignant melanoma. II. Serological evaluation of the immune responses to the injection using allogeneic melanoma cell vaccine].
Takeyama H; Watanabe T; Livingston PO
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1624-33. PubMed ID: 6870307
[TBL] [Abstract][Full Text] [Related]
12. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
13. [Immunology of malignant melanoma].
Misgeld V
Hautarzt; 1973 Dec; 24(12):511-9. PubMed ID: 4599321
[No Abstract] [Full Text] [Related]
14. [Coincidence of melanoma growth and immune status? Virus antigens as a parameter (author's transl)].
Weber G; zur Hausen H; Klughardt G; Galle K
MMW Munch Med Wochenschr; 1981 Feb; 123(8):295-8. PubMed ID: 6261128
[TBL] [Abstract][Full Text] [Related]
15. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of malignant melanoma with vaccinia virus.
Roenigk HH; Deodhar S; St Jacques R; Burdick K
Arch Dermatol; 1974 May; 109(5):668-73. PubMed ID: 4828533
[No Abstract] [Full Text] [Related]
17. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
[TBL] [Abstract][Full Text] [Related]
18. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy].
Lejeune FJ; Bernheim JL; Vanwijck R
Acta Chir Belg; 1974 Mar; 73(2):265-93. PubMed ID: 4450923
[No Abstract] [Full Text] [Related]
20. Serologic response to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates.
Wallack MK; Michaelides M
Surgery; 1984 Oct; 96(4):791-800. PubMed ID: 6091287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
